# SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)*	
Y-mAbs Therapeutics, Inc.	
(Name of Issuer)	
Common stock, par value \$0.0001 per share	
(Title of Class of Securities)	
984241109	
(CUSIP Number)	
08/19/2025	
(Date of Event Which Requires Filing of this Statement)	
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:  Rule 13d-1(b)  Rule 13d-1(c)  Rule 13d-1(d)	
SCHEDULE 13G	
CUSIP No. 984241109	

Names of Reporting Persons

ACORN BIOVENTURES, L.P.
Check the appropriate box if a member of a Group (see instructions)

(a)
(b)
Sec Use Only
Citizenship or Place of Organization

**DELAWARE** 

```
Sole Voting Power
            5
               0.00
Number of
               Shared Voting Power
Shares
Beneficially
               1,175,686.00
Owned by
               Sole Dispositive Power
Each
Reporting
               0.00
Person
               Shared Dispositive
With:
            8 Power
               1,175,686.00
            Aggregate Amount Beneficially Owned by Each Reporting Person
9
            1,175,686.00
            Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
10
            Percent of class represented by amount in row (9)
11
            Type of Reporting Person (See Instructions)
12
            PN
```

## SCHEDULE 13G

## CUSIP No. 984241109

```
Names of Reporting Persons
1
           ACORN CAPITAL ADVISORS GP, LLC
           Check the appropriate box if a member of a Group (see instructions)
2
           (a)
           ☑ (b)
3
           Sec Use Only
           Citizenship or Place of Organization
4
           DELAWARE
              Sole Voting Power
            5
Number of
              Shared Voting Power
Shares
Beneficially
              1,175,686.00
Owned by
              Sole Dispositive Power
Each
Reporting
              0.00
Person
              Shared Dispositive
With:
            8 Power
              1,175,686.00
           Aggregate Amount Beneficially Owned by Each Reporting Person
9
            1,175,686.00
           Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
10
```

```
Percent of class represented by amount in row (9)
11
            2.6 %
            Type of Reporting Person (See Instructions)
12
            00
SCHEDULE 13G
CUSIP No. 984241109
            Names of Reporting Persons
1
            ACORN BIOVENTURES 2, L.P.
            Check the appropriate box if a member of a Group (see instructions)
2
            (a)
             (b)
            Sec Use Only
3
            Citizenship or Place of Organization
4
            DELAWARE
              Sole Voting Power
Number of
              Shared Voting Power
Shares
Beneficially
              1,620,611.00
Owned by
              Sole Dispositive Power
Each
Reporting
              0.00
Person
              Shared Dispositive
With:
              Power
              1,620,611.00
            Aggregate Amount Beneficially Owned by Each Reporting Person
9
            1,620,611.00
            Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
10
            Percent of class represented by amount in row (9)
11
            3.6 %
            Type of Reporting Person (See Instructions)
12
            PN
SCHEDULE 13G
CUSIP No. 984241109
            Names of Reporting Persons
1
            Acorn Capital Advisors GP 2, LLC
2
            Check the appropriate box if a member of a Group (see instructions)
```

```
(a)
            ☑ (b)
3
            Sec Use Only
            Citizenship or Place of Organization
4
            DELAWARE
               Sole Voting Power
               0.00
Number of
               Shared Voting Power
Shares
Beneficially
               1,620,611.00
Owned by
               Sole Dispositive Power
Each
Reporting
               0.00
Person
               Shared Dispositive
With:
               Power
               1,620,611.00
            Aggregate Amount Beneficially Owned by Each Reporting Person
9
            1,620,611.00
            Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
10
            Percent of class represented by amount in row (9)
11
            3.6 %
            Type of Reporting Person (See Instructions)
12
            OO
```

## SCHEDULE 13G

#### **CUSIP No.** 984241109

```
Names of Reporting Persons
1
            Anders Hove
            Check the appropriate box if a member of a Group (see instructions)
2
            (a)
            ☑ (b)
            Sec Use Only
3
            Citizenship or Place of Organization
            UNITED STATES
Number of
               Sole Voting Power
Shares
            5
Beneficially
               0.00
Owned by
               Shared Voting Power
Each
Reporting
               2,796,297.00
Person
               Sole Dispositive Power
With:
               0.00
            8 Shared Dispositive
               Power
```

2,796,297.00
Aggregate Amount Beneficially Owned by Each Reporting Person

2,796,297.00
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Percent of class represented by amount in row (9)

11
6.2 %
Type of Reporting Person (See Instructions)

IN

#### SCHEDULE 13G

Item 1.

Name of issuer:

(a)

Y-mAbs Therapeutics, Inc.

Address of issuer's principal executive offices:

(b)

202 CARNEGIE CENTER, SUITE 301, PRINCETON, NEW JERSEY, 08540.

Item 2.

Name of person filing:

- (a) Acorn Bioventures, L.P. Acorn Capital Advisors GP, LLC Acorn Bioventures 2, L.P. Acorn Capital Advisors GP 2, LLC Anders Hove
  - Address or principal business office or, if none, residence:

(b)
420 Lexington Avenue, Suite 2626, New York, New York 10170
Citizenship:

(c) Acorn Bioventures, L.P. and Acorn Bioventures 2 L.P. are both Delaware limited partnerships. Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC are both Delaware limited liability companies. Anders Hove is a citizen of the United States of America.

Title of class of securities:

- (d)
  Common stock, par value \$0.0001 per share
  CUSIP No.:
- (e) 984241109
- Item 4. Ownership

Amount beneficially owned:

- (a) The information required by Items 4(a) (c) is set forth in Rows (5) (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

  Percent of class:
- (b) The percentages set forth herein are calculated based upon 45,438,420 shares of Common Stock outstanding as of August 4, 2025 as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 filed with the Securities and Exchange Commission on August 8, 2025. %
- (c) Number of shares as to which the person has:
  - (i) Sole power to vote or to direct the vote:

Acorn Capital Advisors GP, LLC is the General Partner of Acorn Bioventures, LP and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn Bioventures, LP. Acorn Capital Advisors GP 2, LLC is the General Partner of Acorn Bioventures 2, L.P. and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn Bioventures 2, L.P.

(ii) Shared power to vote or to direct the vote:

Anders Hove, in his capacity as Manager of each of Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC, may be deemed to beneficially own the shares beneficially owned by each of Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC.

- (iii) Sole power to dispose or to direct the disposition of:
- (iv) Shared power to dispose or to direct the disposition of:
- Item 5. Ownership of 5 Percent or Less of a Class.
- Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

#### Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

#### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

## ACORN BIOVENTURES, L.P.

Signature: Anders Hove

Name/Title: Manager of General Partner

Date: 08/20/2025

ACORN CAPITAL ADVISORS GP, LLC

Signature: Anders Hove Name/Title: Manager Date: 08/20/2025

# ACORN BIOVENTURES 2, L.P.

Signature: Anders Hove

Name/Title: Manager of General Partner

Date: 08/20/2025

Acorn Capital Advisors GP 2, LLC

Signature: Anders Hove Name/Title: Manager Date: 08/20/2025

#### Anders Hove

Signature: Anders Hove Name/Title: Individually Date: 08/20/2025